International Journal of Infectious Diseases
Volume 14, Issue 10 , Pages e868-e875 , October 2010

Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America

  • D. Stamboulian

      Affiliations

    • Fundación Centro de Estudios Infectológicos (FUNCEI), French 3085 (C1425AWK), Buenos Aires, Argentina
    • Corresponding Author InformationCorresponding author. Tel.: +54 11 4803 0720; fax: +54 11 4802 3913.
    • ,
  • G. Lopardo

      Affiliations

    • Fundación Centro de Estudios Infectológicos (FUNCEI), French 3085 (C1425AWK), Buenos Aires, Argentina
    • ,
  • P. Lopez

      Affiliations

    • Centro de Estudios en Infectologia Pediátrica de la Fundación Clinica Valle del Lili, Cali, Colombia
    • ,
  • C. Cortes-Barbosa

      Affiliations

    • Centro de Estudios en Infectologia Pediátrica de la Fundación Clinica Valle del Lili, Cali, Colombia
    • Fundación Valle del Lili, Cali, Colombia
    • ,
  • A. Valencia

      Affiliations

    • Fundación de Santa Fe, Bogota, Colombia
    • ,
  • L. Bedell

      Affiliations

    • Novartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA
    • ,
  • A. Karsten

      Affiliations

    • Novartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA
    • ,
  • P.M. Dull

      Affiliations

    • Novartis Vaccines and Diagnostics, Inc., Cambridge, Massachusetts, USA

Received 18 September 2009 ,Revised 5 March 2010 ,Accepted 12 March 2010.

References 

  1. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894–1901
  2. Bilukha OO, Rosenstein N. National Center for Infectious Diseases, Centers for Disease Control and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2005;54(RR-7):1–21
  3. European Union Invasive Bacterial Infections Surveillance Network. Age distribution of culture confirmed Neisseria meningitidis cases in all reporting countries, by year, 1999-2006. Available at: http://www.euibis.org/php/meningo_age_chart.php?item=culture&country=All+countries. (accessed July 21, 2009).
  4. Gabastou JM, Agudelo CI, Brandileone MC, Castañeda E, de Lemos AP, Di Fabio JL, et al. [Characterization of invasive isolates of S. pneumoniae, H. influenzae, and N. meningitidis in Latin America and the Caribbean: SIREVA II, 2000-2005] (in Spanish). Rev Panam Salud Publica. 2008;24:1–15
  5. Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286:694–699
  6. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report: Emerging Infections Program Network. Neisseria meningitidis, 2007. Atlanta, GA: CDC; 2008. Available at: http://www.cdc.gov/abcs/reports-findings/survreports/mening07.html (accessed July 21, 2009).
  7. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ. 1993;42:21–30
  8. Inés Agudelo C, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis. 2008;14:990–991
  9. Nathan N, Rose AM, Legros D, Tiendrebeogo SR, Bachy C, Bjørløw E, et al. Meningitis serogroup W135 outbreak, Burkina Faso, 2002. Emerg Infect Dis. 2007;13:920–923
  10. Centers for Disease Control and Prevention., Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia—United States, 2000. MMWR Morb Mortal Wkly Rep 2000; 49:345–6.
  11. Weidlich L, Baethgen LF, Mayer LW, Moraes C, Klein CC, Nunes LS, et al. High prevalence of Neisseria meningitidis hypervirulent lineages and emergence of W135:P1.5,2:ST-11 clone in Southern Brazil. J Infect. 2008;57:324–331
  12. Boisier P, Nicolas P, Djibo S, Taha MK, Jeanne I, Maïnassara HB, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis. 2007;44:657–663
  13. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–2210
  14. Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287:1816–1820
  15. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA. 2001;285:177–181
  16. Kelly DF, Pollard AJ, Moxon ER. Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA. 2005;294:3019–3023
  17. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J. 2007;26:716–722
  18. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19:142–164
  19. Hassan-King MK, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect. 1988;16:55–59
  20. Moore PS, Harrison LH, Telzak EE, Ajello GW, Broome CV. Group A meningococcal carriage in travelers returning from Saudi Arabia. JAMA. 1988;260:2686–2689
  21. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ. 2003;326:365–366
  22. Kelly DF, Snape MD, Clutterbuck EA, Green S, Snowden C, Diggle L, et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood. 2006;108:2642–2647
  23. Perrett KP, Snape MD, Ford KJ. Safety, immunogenicity, and immune memory of a non-adjuvanted meningococcal (serogroups A, C, W-135, and Y) glycoconjugate vaccine in healthy infants. Paper presented at the Infectious Diseases Society of America 44th Annual Meeting. Toronto, Canada, October 12-15, 2006.
  24. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173–184
  25. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM, et al. Tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in 2- to 10-year-old children. Vaccine. 2010;28:657–663
  26. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86–91
  27. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49:e1–10
  28. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226
  29. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria–tetanus–pertussis containing acellular pertussis. Lancet. 1999;354:2063–2068
  30. Bröker M, Dull PM, Rappuoli R, Constantino P. Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages. Vaccine. 2009;27:5574–5580
  31. Granoff DM, Boies EG, Munson RS. Immunogenicity of Haemophilus influenzae type b polysaccharide–diphtheria toxoid conjugate vaccine in adults. J Pediatr. 1984;105:22–27
  32. Jackson LA, Neuzil KM, Nahm MH, Whitney CG, Yu O, Nelson JC, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2007;25:4029–4037
  33. de Roux A, Schmöle-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis. 2008;46:1015–1023

PII: S1201-9712(10)02419-7

doi: 10.1016/j.ijid.2010.03.017

International Journal of Infectious Diseases
Volume 14, Issue 10 , Pages e868-e875 , October 2010

Article Tools

* Image Usage & Resolution